MedTrace Logo

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

NCT02661815 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-11-08

Study results available
· View outcomes & findings →

Summary

Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study. This research study is studying a combination of a new chemotherapy drug called Ricolinostat together with the chemotherapy Paclitaxel and a drug called Bevacizumab as a possible treatment for this diagnosis.

Conditions

Interventions

DRUG

Paclitaxel

Please see arm/group description.

DRUG

Ricolinostat

Please see arm/group description.

DRUG

Bevacizumab

Please see arm/group description.

Sponsors & Collaborators

Principal Investigators

  • Joyce Liu, MD MPH · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-15
Primary Completion
2017-06-28
Completion
2017-07-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02661815 on ClinicalTrials.gov